Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.

Five heavily pretreated HIV-infected children were put on amprenavir and delavirdine plus two nucleoside reverse transcriptase inhibitors to boost amprenavir levels and to use the antiretroviral activity of a non-nucleoside reverse transcriptase inhibitor. No data are available about this combination in children. It was well tolerated, and the median reduction in viral load was 1.5 log after 18 months. Delavirdine boosted amprenavir trough levels more than 10-fold, and delavirdine trough levels remained several fold above susceptible HIV strains.